- AMB302, co-developed with
GeneQuantum, targets FGFR3, which is overexpressed in a range of solid tumors.
- In addition to combination therapy with temozolomide (TMZ), AMB302 demonstrated enhanced antitumor activity when
combined with immune checkpoint inhibitors (ICIs), supporting its potential as a combination partner for ICI-based therapies.
- In non-human primate studies,
AMB302 was well tolerated at doses up to 60 mg/kg without severe adverse
effects.